Gilead Sciences Inc. ($GILD) Stock Forecast: Up 5.3% Today

What is Gilead Sciences Inc.?

Gilead Sciences (NASDAQ: GILD) is a biopharmaceutical company known for its innovative treatments in areas such as HIV, hepatitis C, and more.

Why is Gilead Sciences Inc. going up?

GILD stock is up 5.3% on Oct 17, 2025 19:00

• A Buy rating and raised price target for Gilead Sciences by Citigroup analyst boosted investor confidence in the stock.
• Positive sentiment from CNBC's "Final Trades" segment likely attracted more attention from traders, contributing to the bullish movement.
• Endorsement from industry experts and media coverage could have sparked increased buying interest, leading to the strong bullish movement in GILD stock today.

GILD Price Chart

GILD Technical Analysis

GILD News

Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades' - Gilead Sciences ( NASDAQ:GILD ) , Coinbase Global ( NASDAQ:COIN )

On CNBC's "Halftime Report Final Trades," Rob Sechan, CEO of NewEdge Wealth, named Gilead Sciences, Inc. ( NASDAQ:GILD ) as his final trade. Lending support to his choice, Citigroup analyst Geoff Meacham maintained a Buy rating for Gilead Sciences on Oct. 8, raising the price target from $125 ...

https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/10/48173116/gilead-coinbase-rocket-lab-and-a-tech-stock-on-cnbcs-final-trades

Trending Today

Ethereum ($ETH) Crypto Forecast: Up 5.1% Today

Solana ($SOL) Crypto Forecast: Up 5.1% Today

Jupiter ($JUP) Crypto Forecast: Up 5.1% Today

XRP ($XRP) Crypto Forecast: Up 5.5% Today

Aave ($AAVE) Crypto Forecast: Down 12.3% Today

Monero ($XMR) Crypto Forecast: Down 6.4% Today

Wingstop Inc. ($WING) Stock Forecast: Up 5.0% Today

Jefferies Financial Group Inc. ($JEF) Stock Forecast: Up 6.3% Today

Gilead Sciences Inc. ($GILD) Stock Forecast: Up 5.3% Today

American Express Company ($AXP) Stock Forecast: Up 8.0% Today

Gilead Sciences Inc. Price History

09.03.2025 - GILD Stock was down 5.1%

• Gilead Sciences (GILD) exhibited bearish movement, closing at $112.39 with a +0.45% change from the previous close.
• The positive momentum surrounding Gilead Sciences amid market decline could be linked to internal developments within the company.
• Various factors such as tariff tensions, geopolitical events, and uncertainties related to the Fed may have influenced the overall market sentiment, potentially overshadowing Gilead's performance.
• Attention from investors may have shifted towards other companies like Amazon and Alphabet, affecting Gilead Sciences' performance and contributing to its bearish movement.

07.10.2024 - GILD Stock was up 6.5%

• Gilead Sciences has consistently outperformed the market over the past 20 years, showcasing strong growth and investor confidence.
• The upcoming Q3 earnings report has likely sparked investor optimism, especially regarding the performance of GILD's HIV franchise and oncology sales.
• Despite a slight market dip, Gilead Sciences managed to gain, indicating resilience and potential positive news or market sentiment surrounding the company.

17.09.2025 - GILD Stock was up 5.3%

• A Buy rating and raised price target for Gilead Sciences by Citigroup analyst boosted investor confidence in the stock.
• Positive sentiment from CNBC's "Final Trades" segment likely attracted more attention from traders, contributing to the bullish movement.
• Endorsement from industry experts and media coverage could have sparked increased buying interest, leading to the strong bullish movement in GILD stock today.

06.04.2025 - GILD Stock was down 5.1%

• GILD saw a downward trend today after disappointing first-quarter results, particularly in the oncology sector.
• Advice for investors to adopt a cautious approach indicates uncertainty about the stock in the near future.
• The market's response to the earnings shortfall underscores the significance of consistent performance in crucial business divisions, like oncology, to uphold investor trust in pharmaceutical firms like GILD.

08.07.2025 - GILD Stock was up 9.8%

• GILD stock had a strong uptrend today.
• Strategies to generate monthly dividend income from owning GILD shares before Q2 earnings are highlighted.
• The surge in the stock price may be linked to positive investor outlook on GILD's upcoming earnings and dividend potential.
• Favorable market sentiment towards income-generating stocks like GILD might have contributed to the stock's uptick.

25.06.2024 - GILD Stock was up 5.1%

• Gilead Sciences witnessed a strong bullish movement on the market.
• This positive market sentiment stems from the favorable reception of new data on HIV treatments showcased at AIDS 2024. The data revealed significant advancements such as 100% suppression rates in Hispanic patients, the introduction of promising weekly dosing options, and innovative long-acting therapies.
• Additionally, the bullish positioning of high-profile investors in Gilead Sciences, supported by options data available to the public, likely contributed to the upward momentum.
• The recent announcement of a twice-yearly injection providing 100% protection against HIV in women, as emphasized in a recent study, has also added to the positive outlook on Gilead's future prospects within the HIV treatment sector.

25.06.2024 - GILD Stock was up 6.3%

• Gilead Sciences' stock surged today following the groundbreaking results of its lenacapavir HIV prevention trial, showcasing 100% efficacy in protecting against HIV.
• The positive news of the twice-yearly injectable's superior performance compared to daily oral PrEP likely boosted investor confidence in Gilead's innovative pipeline.
• The competition in the HIV treatment space, highlighted by another company matching Gilead's three-drug combo with a two-drug regimen, also underscored the potential for growth and market leadership in this sector.
• Overall, Gilead's advancements in HIV prevention and treatment are driving optimism among investors, propelling the stock to a bullish trajectory.

08.07.2025 - GILD Stock was up 8.9%

• In the second quarter, Gilead Sciences posted strong financial results, exceeding expectations with an adjusted EPS of $2.01 and revenue of $7.08 billion. This robust performance likely drove the positive movement in the stock price.
• Sales of key products such as Biktarvy and Descovy showed notable increases of 9% and 35% respectively, demonstrating the company's ability to meet market demand effectively and boost revenue.
• Investors showed optimism before Gilead Sciences' Q2 earnings release, fueling the surge in the stock price as they looked to benefit from potential dividend income and the company's growth prospects.

10.03.2025 - GILD Stock was down 5.6%

• GILD had a strong bearish movement despite a slight increase in its stock price in the previous trading day.
• The conflicting reports of GILD ascending while the market falls may have caused confusion among investors, leading to profit-taking and a bearish trend.
• Investors might be concerned about Gilead Sciences falling behind the market, possibly due to competition in the biopharmaceutical sector or delays in drug development.
• The overall market sentiment and the specific news about GILD's performance could have contributed to the bearish movement of the stock today.

12.01.2025 - GILD Stock was up 7.5%

• Gilead Sciences experienced a notable increase in its stock price due to the announcement of better-than-expected fourth-quarter financial results and optimistic FY25 adjusted EPS guidance.
• The market responded positively to Gilead's strategic collaborations, including the recent partnership with LEO Pharma involving significant upfront payments and potential milestones.
• Despite prevailing market pessimism and concerns from institutional investors about Gilead Sciences options trading, the company's robust performance and promising future outlook appear to have driven the stock upwards.

12.01.2025 - GILD Stock was up 8.0%

• Gilead Sciences reported Q4 earnings, with analysts expecting $1.70 EPS and $7.14B in revenue, potentially exceeding forecasts and boosting investor confidence.
• The company's deal with LEO Pharma, including significant upfront payments and future milestones, may have positively influenced market sentiment towards Gilead.
• Despite some bearish options trading activity, the overall positive outlook on GILD's earnings and performance in key therapeutic areas like HIV and oncology likely contributed to the bullish movement.
• Investors are closely watching Gilead's HIV franchise performance and oncology sales, indicating a strong interest in the company's core revenue-generating segments.

12.01.2025 - GILD Stock was up 7.1%

• Gilead Sciences experienced a strong bullish movement today following the release of its Q4 financial results and optimistic outlook for 2025.
• The company reported a 6% increase in Q4 revenue, surpassing analyst expectations, and raised its dividend, signaling financial strength and confidence in future performance.
• The market reacted positively to Gilead's announcement of launching Lenacapavir for HIV prevention, indicating potential growth opportunities in its product pipeline.
• Overall, Gilead's solid financial performance and strategic developments have instilled investor confidence, driving the stock price higher in today's trading session.